Raymond Bergan 教授

Unit: Oregon Health & Science University (OHSU)

Dr. Raymond Bergan is the Chief of Division of Hematology and Medical Oncology at Oregon Health & Science University (OHSU), and the Director of Bergan Basic Research Laboratory.  He also serves as the Co-Leader for the Translational Oncology Program for the Knight Cancer Institute. He is also the Chair of the Prevention committee for the ECOG-ACRIN (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network) cancer clinical trials cooperative group. Dr. Bergan directs both basic laboratory program and clinical research program, both are heavily funded by the National Cancer Institute (NCI) of the National Institutes of Health (NIH), and several other large federal funding agencies for many years. He has published over hundreds of high-impact articles. Dr. Bergan is an internationally renowned expert in the fields of chemoprevention, drug discovery and novel cancer therapy development. In his research in drug development, he has several patented drugs. His research findings on one of the patented synthesized small molecule, KBU2046, has been shown to inhibit human prostate cancer cell motility and metastasis at nM concentration, the finding is recently published by Nature Communication. 

中文：

Raymond Bergan教授

美国俄勒冈健康与科学大学血液肿瘤科主任

奈特癌症研究所副所长

Bergan基础研究实验室主任

ECOG-ACRIN预防委员会癌症临床试验方向的主席

Bergan教授主要从事肿瘤预防的临床试验研究及新药开发工作，是化学预防，药物发现和癌症治疗发展领域的国际知名专家，在JNCI、JCO等高影响因子杂志，发表论文百篇。在药物开发方向中，拥有几种专利药物，其中一项专利在Nature Communication发表。